Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04136418
Other study ID # Worktribe 833757
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 7, 2020
Est. completion date March 31, 2023

Study information

Verified date October 2022
Source University of Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

COPD is a common complex disease with debilitating breathlessness; mortality and reduced quality of life, accelerated by frequent lung attacks (exacerbations). Changes in breathlessness, cough and/or sputum production often change before exacerbations but patients cannot judge the importance of such changes so they remain unreported and untreated. Remote monitoring systems have been developed but none have yet convincingly shown the ability to identify these early changes of an exacerbation and how severe they can be. This study asks if a smart digital health intervention (COPDPredict™) can be used by both COPD patients and clinicians to improve self-management, predict lung attacks early, intervene promptly, and avoid hospitalisation. COPDPredict™ consists of a patient-facing App and clinician-facing smart early warning decision support system. It collects and processes information to determine a patient's health through a combination of wellbeing scores, lung function and biomarker measurements. This information is combined to generate personalised lung health profiles. As each patient is monitored over time, the system detects changes from an individual's 'usual health' and indicates the likelihood of imminent exacerbation of COPD. When this happens, alerts are sent to both the individual and the clinician, with instructions to the patient on what actions to take. Any advice from clinicians can be exchanged via the App's secure messaging facility. If patients have followed the action plan but fail to improve or if an episode triggers an 'at high risk alert', clinicians are further prompted to case manage and intervene with escalated treatment, including home visits, if necessary. The COPDPredict™ intervention aims to assist patients and clinicians in preventing clinical deterioration from COPD exacerbations with prompt appropriate intervention. This study will randomise 384 patients who have frequent exacerbations, from hospitals in the West Midlands, to either (1) standard self-management plan (SSMP) with rescue medication (RM), or (2) COPDPredict™ and RM.


Description:

Changes in dyspnoea, coughing and/or sputum production often precede exacerbations but as symptoms vary within-same day and across days, patients cannot easily judge the significance of such changes with the result that exacerbations remain unreported and untreated. Furthermore due to heterogeneity amongst COPD patients, predictions must be personalised to be clinically meaningful. Remote monitoring and POC systems have evolved rapidly but none have yet convincingly demonstrated the capability to predict exacerbations and stratify episode severity. To address the above problem, COPDPredictTM has been created and developed. This System automatically processes information that is regularly sent by patients using COPDPredictTM), which connects to peripheral monitors via Bluetooth and uses intelligent software to determine a patient's health through a combination of wellbeing scores, lung function and measurements of key biomarkers in blood and saliva. The clinical team has access to a secure web portal (dashboard) which allows them to monitor patient data, case manage and make informed decisions on clinical practice. Depending on the degree of change from a given patient's 'usual health', timely alerts are sent to the individual, with sign-posting to an action plan. Alerts are also sent to clinicians who support and advise patients via App's secure messaging facility. If patients fail to improve with self-treat plan or if an episode triggers an 'at high risk alert' from the start, clinicians are prompted to be involved and intervene with escalated treatment The Clinician facing dashboard allows for "real-time" case management and the ability to remotely monitor the patients and facilitate interaction. Clinicians can choose to escalate treatments based on the results being transmitted by the patients. This clinical investigation asks if COPDPredictTM can be used by patients with COPD at home and the clinicians managing the patients to improve self-management and help them identify exacerbations, intervene promptly and avoid hospitalisation. The clinical investigation will randomise 384 patients, from 4 hospitals in the West Midlands. United Kingdom, who have frequent AECOPD to use either the SSMP and RM (if needed according to the SSMP) or the COPDPredict App and RM (if needed according to the App self-management plan or clinician input).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 384
Est. completion date March 31, 2023
Est. primary completion date March 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Clinically diagnosed chronic obstructive pulmonary disease (COPD), confirmed by post-bronchodilator spirometry and defined as a ratio of Forced Expiratory VolumeFEV1 to Forced Vital Capacity <0.7 and <lower limit of normal for age post bronchodilator use - =2 Acute Exacerbations of COPD (AECOPD) in the previous 12 months according to the patient and/or =1 hospital admission for AECOPD - Exacerbation free for at least 6 weeks - An age of at least 18 years - Willing and able to comply with the data collection process out to 12 months from randomisation - Ability to consent - Ability to use intervention as judged by the investigator at screening, upon demonstration of the system to the patient Exclusion Criteria: - Life expectancy < 12 months - Patients with active infection, unstable co-morbidities at enrolment or very severe comorbidities such as grade IV heart failure, renal failure on haemodialysis or active neoplasia or significant cognitive impairment;

Study Design


Related Conditions & MeSH terms


Intervention

Device:
COPDPredict mobile App
An App on a mobile device is used by the patient to track the status of their COPD and inform the patient's care team
Other:
Usual care
Patients self-manage their COPD using prescribed medication in accordance with basic guidance information

Locations

Country Name City State
United Kingdom University Hospitals Coventry & Warwickshire Trust Coventry England

Sponsors (2)

Lead Sponsor Collaborator
University of Birmingham University Hospitals of North Midlands NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Blood C-Reactive Protein (CRP) levels Variation in blood CRP levels during exacerbations For a period of 12 months post randomisation
Other Salivary C-Reactive Protein (CRP) levels Variation in salivary CRP levels during exacerbations For a period of 12 months post randomisation
Primary AECOPD-related hospital admissions The number of AECOPD-related hospital admissions For a period of 12 months post randomisation
Secondary Total inpatient days Number of days a patient is in hospital For a period of 12 months post randomisation
Secondary Number of COPD exacerbations reported by the patient Number of patient defined exacerbations For a period of 12 months post randomisation
Secondary Number of A&E visits Number of times that a patient reports attending Accident & Emergency (A&E) due to COPD exacerbations For a period of 12 months post randomisation
Secondary Symptom control markers using Anthonisen criteria Presence of symptom control markers (breathlessness, colour of sputum, amount of sputum produced) For a period of 12 months post randomisation
Secondary End-user experience of the App technology acceptability usability/utility via bespoke qualitative questionnaires and interviews For a period of 12 months post randomisation
Secondary COPD specific health-related quality of life Assessed by the COPD Assessment Test validated questionnaire 3, 6, 9 and 12 months post randomisation
Secondary Health-related quality of life Assessed by the EQ-5D-5L validated questionnaire 3, 6, 9 and 12 months post randomisation
Secondary Lifestyle choices assessed via either responses to bespoke questions on the App or bespoke questionnaires and interviews 3, 6, 9 and 12 months post randomisation
Secondary Functional expiratory volume (FEV1) Functional expiratory volume assessed by spirometry At 12 months post randomisation
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy